Cardiff Oncology, Inc. expects to release top-line data from a Phase II study of its PLK1 inhibitor onvansertib in first-line RAS-mutated metastatic colorectal cancer (mCRC) around mid-2024, but data from a discontinued study in second-line patients has provided evidence that the theory behind the ongoing trial is sound.
Key Takeaways
-
Cardiff is enrolling a Phase II study in first-line mCRC for its PLK1 inhibitor that it hopes will yield overall response data by mid-2024.
- ...
The San Diego biotech has been waging a two-front battle as it tries to make its cash last long enough to prove that its PLK1 inhibitor can boost the effectiveness...
Read the full article – start your free trial today!
Join thousands of industry professionals who rely on Scrip for daily insights
- Start your 7-day free trial
- Explore trusted news, analysis, and insights
- Access comprehensive global coverage
- Enjoy instant access – no credit card required
Already a subscriber?